MIMEDX Adds Fibrillar Collagen Wound Dressing to its Lineup

MiMedx Group Inc. has forged an agreement with TELA Bio Inc. for exclusive rights to its manufacturing and supply agreement with Regenity Biosciences that will allow the company to add xenograft products to its Advanced Wound Care and Surgical solutions portfolio.
 
“We are excited to announce the formation of this partnership with Regenity and believe it is an important step toward achieving our long-term growth plan,” MIMEDX CEO Joseph H. Capper said. “As we have stated, one of our strategic priorities is to augment our placental-derived product portfolio with xenografts and/or synthetic skin substitutes in order to meet the needs of a greater number of customers, domestically and abroad. We are thrilled to begin this collaboration with Regenity, which will add highly complementary products to our portfolio and improve our position in the wound and surgical markets we serve.”
 
As part of the manufacturing and supply agreement, MIMEDX will immediately add to its portfolio a U.S. Food and Drug Administration 510(k)-cleared, bovine-derived collagen matrix product for managing moderately to heavily exudating wounds and to control minor bleeding. The collagen in this product serves as a dressing that allows for cell adhesion and migration into the wound site and supports wound healing. It is provided in particulate form allowing it to be molded or packed to conform to various wound types such as pressure ulcers, venous stasis ulcers, diabetic ulcers, acute wounds, for example trauma and surgical wounds, and partial-thickness burns.
 
“We are excited to pair this product with our commercial channel and support network to offer surgeons, clinicians, and their patients another particulate solution that can be used for acute and chronic wound management,” Capper stated. “Additionally, we look forward to partnering with Regenity and leveraging their expertise to bring other products in our pipeline to market in the future.”
 
Under the terms of the agreement, MIMEDX will initially pay TELA Bio $5 million; additional future payments will vary between $3 million (minimum) and $7 million (maximum) based on net sales of the bovine-derived collagen matrix product over the next two years.
 
MIMEDX provides wound care, burn, and surgical products. 
 
TELA Bio Inc. is a commercial-stage medical technology company that provides technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. The company provides surgeons with economically effective soft-tissue reconstruction solutions that leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials. 
 
Regenity Biosciences is the global developer and manufacturer of bioresorbable technologies to repair and regenerate natural tissue and bone for various markets including dental, spine, orthopedic, neurosurgery, ENT and nerve repair. Founded in 1997, Regenity (formerly Collagen Matrix Inc.) is headquartered in Paramus, N.J., with manufacturing locations in Oakland and Allendale, N.J., and Groningen, the Netherlands. Regenity’s product portfolio includes various collagen-based and synthetic polymer solutions that support the company’s platform for tissue and bone regeneration. Regenity develops proprietary products that are sold to OEM customers on either a contract or private label basis and offers partnership opportunities including contract product development and manufacturing services.